Collegium Pharmaceutical (NASDAQ:COLL) Stock Price Up 5.3%

Collegium Pharmaceutical Inc (NASDAQ:COLL)’s share price rose 5.3% during mid-day trading on Friday . The stock traded as high as $11.66 and last traded at $11.52, approximately 190,544 shares changed hands during trading. A decline of 49% from the average daily volume of 374,391 shares. The stock had previously closed at $10.94.

COLL has been the subject of several recent analyst reports. BidaskClub upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday. ValuEngine upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, August 8th. Cantor Fitzgerald restated an “overweight” rating and set a $24.00 price objective (down from $35.00) on shares of Collegium Pharmaceutical in a research report on Thursday, August 8th. Finally, HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a research report on Friday, May 3rd. They set a “buy” rating and a $23.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Collegium Pharmaceutical currently has a consensus rating of “Buy” and an average target price of $24.33.

The company has a debt-to-equity ratio of 0.23, a current ratio of 1.25 and a quick ratio of 1.20. The company has a market cap of $370.21 million, a PE ratio of -9.68 and a beta of 0.54. The company’s 50 day simple moving average is $11.43 and its two-hundred day simple moving average is $13.70.



Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, August 7th. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.19) by $0.05. The company had revenue of $75.04 million during the quarter, compared to analyst estimates of $75.77 million. Collegium Pharmaceutical had a negative net margin of 7.45% and a negative return on equity of 26.10%. Collegium Pharmaceutical’s revenue was up 2.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.40) earnings per share. Sell-side analysts expect that Collegium Pharmaceutical Inc will post -0.38 EPS for the current fiscal year.

In other Collegium Pharmaceutical news, CEO Joseph Ciaffoni sold 7,436 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $11.59, for a total transaction of $86,183.24. Following the completion of the transaction, the chief executive officer now owns 190,755 shares of the company’s stock, valued at $2,210,850.45. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Michael Thomas Heffernan sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $11.26, for a total transaction of $281,500.00. Following the completion of the transaction, the director now directly owns 132,069 shares of the company’s stock, valued at approximately $1,487,096.94. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 66,144 shares of company stock valued at $754,506. 8.08% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. ClariVest Asset Management LLC purchased a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $529,000. Schroder Investment Management Group purchased a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $256,000. Nuveen Asset Management LLC purchased a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $2,622,000. OneAscent Financial Services LLC purchased a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $275,000. Finally, AQR Capital Management LLC purchased a new position in shares of Collegium Pharmaceutical in the second quarter valued at approximately $320,000. 96.29% of the stock is owned by institutional investors and hedge funds.

Collegium Pharmaceutical Company Profile (NASDAQ:COLL)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, heating, and injecting.

Featured Article: What is the Quick Ratio?

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.